Stocks and Investing
Stocks and Investing
Tue, November 14, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Paul Matteis Initiated (VTGN) at Strong Buy and Held Target at $12 on, Nov 14th, 2023
Paul Matteis of Stifel, Initiated "Vistagen Therapeutics, Inc." (VTGN) at Strong Buy and Held Target at $12 on, Nov 14th, 2023.
Paul has made no other calls on VTGN in the last 4 months.
There is 1 other peer that has a rating on VTGN. Out of the 1 peers that are also analyzing VTGN, 0 agree with Paul's Rating of Hold.
This is the rating of the analyst that currently disagrees with Paul
- Jason McCarthy of "Maxim Group" Maintained at Strong Buy and Held Target at $30 on, Tuesday, September 5th, 2023
Contributing Sources